Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

77.4%

48 terminated/withdrawn out of 62 trials

Success Rate

9.4%

-77.2% vs industry average

Late-Stage Pipeline

47%

29 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

4 recruiting2 with results28 terminated20 withdrawn

Enrollment reporting

Analytics

Phase 3

15(25.9%)

Phase 4

14(24.1%)

N/A

11(19.0%)

Phase 2/3

10(17.2%)

Phase 2

4(6.9%)

Phase 1

2(3.4%)

Phase 1/2

1(1.7%)

Early Phase 1

1(1.7%)

58Total

Phase 3(15)

Phase 4(14)

N/A(11)

Phase 2/3(10)

+4 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (62)

Showing 20 of 62 trials

NCT07640256Phase 4Completed

Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia

Role: lead

NCT07430137Not ApplicableNot Yet Recruiting

Blink Reminders and Meibomian Gland Loss in Digital Screen Users

Role: lead

NCT05587205Phase 1Recruiting

Safety and Tolerability of EO2002

Role: lead

NCT05636579Phase 1Recruiting

Study to Assess Safety and Tolerability of Multiple Doses of EO2002

Role: lead

NCT07175311Recruiting

Vascular Changes Associated With Endophthalmitis.

Role: lead

NCT07095907Not ApplicableRecruiting

Post-surgical Functional Results in Patients With Epiretinal Membrane Undergoing Controlled Macular Detachment

Role: lead

NCT05736081Phase 4Completed

Short-term Effect of Intravitreal Dexamethasone Implant in Refractory Diabetic Macular Edema

Role: lead

NCT00555594Phase 2/3Completed

Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

Role: lead

NCT00346814Phase 2/3Unknown

Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

Role: lead

NCT00406172Phase 3Withdrawn

Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)

Role: lead

NCT00418431Phase 2/3Withdrawn

Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

Role: lead

NCT00496405Phase 4Withdrawn

Unilateral Bevacizumab for Bilateral Diabetic Macular Edema

Role: lead

NCT00347711Phase 3Withdrawn

Bevacizumab and Retinal Vascular Occlusions

Role: lead

NCT00403702Phase 2/3Withdrawn

Comparison High-density Silicone Oils in Retinal Detachment

Role: lead

NCT00406744Phase 3Terminated

Efficacy of Retreatments With Intravitreal Bevacizumab

Role: lead

NCT00417716Phase 3Withdrawn

Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema

Role: lead

NCT00417833Phase 2/3Terminated

Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

Role: lead

NCT00567372Phase 4Withdrawn

POSTERIOR SUB-TENON'S Avastin

Role: lead

NCT00599820Phase 3Terminated

Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

Role: lead

NCT00600236Phase 3Withdrawn

HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population

Role: lead